The results indicated that gender, lymph node metastasis, pleural hyperemia, pleural leukoma, pleural adhesion, treatment regimen, serum CEA level, and gene mutation type had no statistically significant effects on 2 years OS and PFS in patients with 19-del mutation and patients with 21-L858R mutant pleural metastasis (Table 5). Here, CEACAM5 is linked to metastatic malignant neoplasm in the lymph nodes.